What IDEXX Laboratories Investors Missed Before The Fall

If you had looked at IDEXX Laboratories on 1 January and decided to sit it out, the eventual result may have felt like an escape rather than a miss. Investors who held IDEXX Laboratories from the start of the year are down 22.7%, including dividends. Since then, upbeat headlines on AI diagnostics, Cancer Dx adoption, and raised earnings guidance have piled up. What early assumption about pet demand, pricing power, or competitive risk was already on record that might have flagged this gap?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

This theme extends beyond IDEXX Laboratories. See which of 34 healthcare AI stocks may still merit a closer look.

The Two IDEXX Stories Investors Had To Weigh

The shares cost US$677 at the start of the period, which forced anyone looking at IDEXX Laboratories to choose between two sharply different stories about the same business.

The bullish Narrative put Fair Value at US$765, framed around strong adoption of AI-enabled diagnostics and software. This could lift recurring revenue and margins as IDEXX Laboratories deepened its ecosystem with tools like Cancer Dx and inVue Dx.

The bearish view set Fair Value at US$417 and focused on shrinking pet ownership, weaker clinic visits, rising competition, and higher compliance costs that might erode pricing power and slow recurring consumables growth.

What The IDEXX Evidence Actually Tested

IDEXX Laboratories reported Q2 2026 revenue of US$1,216.6m and net income of US$338.4m, with net margin at 27.8% versus 26.5% a year earlier. That outcome leaned toward the bullish recurring revenue and margin story. The acquisition of CoVetAI and the integration of SDMA into Catalyst profiles and broader fecal testing upgrades still left the long term pet ownership worries unresolved, so the evidence cut both ways.

The useful takeaway is where the 2025 Narratives were most exposed. For a company like IDEXX Laboratories, investors can track reported recurring diagnostics and software streams and the net margin line against any thesis that leans on durable pricing power and instrument driven consumables.

What You Would Be Paying For In IDEXX Laboratories Today

IDEXX Laboratories now trades at US$518, after a loss of 22.7% from the start of the year. The selected Narrative sees Fair Value above that level, built around recurring diagnostics, software usage, and a growing VetLab and inVue Dx footprint.

For that higher Fair Value to be reached, a buyer today would need recurring diagnostics per clinic visit to deepen enough to support the current margin and utilization assumptions.

"The main factor that has to go right is that IDEXX Laboratories converts underpenetrated veterinary diagnostics demand into higher bloodwork inclusion and utilization across an expanding VetLab and inVue Dx installed base, even with softer clinical visit trends."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Go Straight To The Source

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 41% below our estimate - shifts toward commercial and specialized lending supported by low cost business deposits.
• Company 2 - 48% below our estimate - expands defense oriented satellite connectivity through acquisition breadth and extended service arrangements.
• Company 3 - 34% below our estimate - builds high horsepower power systems as new capacity and data center contracts develop.

Those are three of them. See all 30 potentially undervalued companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com